Tremors and Agitation Following Low-Dose Intravenous Hydromorphone Administration in a Patient with Kidney Dysfunction

  title={Tremors and Agitation Following Low-Dose Intravenous Hydromorphone Administration in a Patient with Kidney Dysfunction},
  author={David J. Gagnon and Kevin Jwo},
  journal={Annals of Pharmacotherapy},
  pages={e34 - e34}
OBJECTIVE To report a case of tremors and agitation associated with the administration of low doses of intravenous hydromorphone in a patient with acute kidney injury in the setting of chronic kidney disease. CASE SUMMARY A 91-year-old man was admitted for a left intertrochanteric hip fracture. On hospital days 1 and 2, the patient received hydromorphone 1 mg intravenously for pain. By hospital day 3, the patient had received a total of 3.5 mg of hydromorphone. He then became tremulous and… 
4 Citations
Patients with Renal Failure Who Received a Small Dose of Hydromorphone and Presented with Neurotoxicity
Although there are reports of neurotoxicity caused associated with the use of high-dose, long-term hydromorphone in patients with renal failure, neurotoxicity may be shown even with small doses and short-term administration.
Extracorporeal Removal of Poisons and Toxins.
The level of evidence for extracorporeal treatment of a number of individual toxins have been systematically reviewed within the current decade by the Extracorpreal Treatment in Poisoning workgroup, which has published treatment recommendations with an improved evidence base.
Relevante Interaktionen von Analgetika und Koanalgetika mit onkologischen Systemtherapeutika – wann wird es gefährlich?
Although the number of available effective analgesic substances has stagnated for decades, the market for available and often highly effective oncological drugs has developed almost explosively and the probability of clinically relevant and even fatal drug-drug interactions is increased.


Hydromorphone neuroexcitation.
A retrospective chart review was performed on 48 terminally ill hospice patients who received continuous parenteral hydromorphone for pain control to find that agitation, myoclonus, and seizures were not associated with the patients gender, age, or diagnosis but found that agitation was associated in patients with known metastatic disease.
Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone.
Parenteral hydromorphone has few neuroexcited symptoms until H3G accumulates past a neurotoxic threshold, such as might occur with increasing dose or duration, which, when exceeded, causes neuroexcitatory symptoms to manifest.
Palliative Care Round: Cognitive Failure and Coma after Renal Failure in a Patient Receiving Captopril and Hydromorphone
An 85-year-old woman with advanced breast carcinoma was admitted to the palliative care unit and was started on mexiletine 100 mg twice a day in an effort to improve her neuropathic pain, together with dexamethasone 10 mg once a day.
Neurotoxic effects associated with antibiotic use: management considerations.
The clinical manifestations of antibiotic-induced neurotoxic effects, the underlying mechanisms and management strategies have been reviewed and high degree of vigilance in critically ill patients is essential in identifying a potentially serious, though reversible complications of antibiotic therapy.
Cephalosporin-Induced Neurotoxicity: Clinical Manifestations, Potential Pathogenic Mechanisms, and the Role of Electroencephalographic Monitoring
Knowledge and awareness of the neurotoxic clinical manifestations, EEG findings, and underlying mechanisms are essential for clinicians in identifying and treating this potentially lethal but reversible complication of cephalosporin therapy.
Ceftriaxone-induced acute reversible encephalopathy in a patient treated for a urinary tract infection.
A case of encephalopathy with generalised triphasic waves in a patient with pre-existent cerebrovascular disease who was treated with ceftriaxone for a urinary tract infection is described.
A method for estimating the probability of adverse drug reactions
It was shown that the ADR probability scale has consensual, content, and concurrent validity and may be applicable to postmarketing drug surveillance.